Immune response to pneumococcal polysaccharide vaccine in adults with chronic plaque psoriasis treated with alefacept - 14/09/11
, James Krell, MD b, Neil Korman, MD, PhD c, Barbara Mathes, MD dVaccine Study Investigators
Reprint requests: Charles Lynde, MD, Lynde Center for Dermatology, 5762 Hwy 7 E, Suite 201, Markham, ON L3P 1A8, Canada.Abstract |
Background |
Alefacept is a T cell–modulating biologic therapy for psoriasis that could affect patients' ability to mount immune responses.
Objective |
This open-label, phase IV, multicenter study assessed the ability of adults with chronic plaque psoriasis receiving alefacept to generate antibodies to a pneumococcal polysaccharide vaccine (PPV).
Methods |
Patients were treated with a standard 12-week course of alefacept and administered the 23-valent PPV at week 6. Antipneumococcal antibodies were measured at baseline and weeks 6, 9, 12, and 33. The primary end point was the percentage of patients with a 2-fold or greater increase from prevaccination (week 6) to 6 weeks postvaccination (week 12) in antibody titers to 2 or more of 5 designated PPV antigens.
Results |
Of 43 patients enrolled, 42 were included in the full analysis set, with 86% of patients exhibiting a 2-fold or greater increase and 57% of patients exhibiting a 4-fold or greater increase in antibody titers to 2 or more of 5 designated antigens from prevaccination to 6 weeks postvaccination. At 6 months postvaccination, 78% of patients had a 2-fold or greater increase and 47% of patients had a 4-fold or greater increase in antibody titers to 2 or more of the 5 designated antigens. There were statistically significant increases in mean antibody titers to all 23 antigens in PPV from prevaccination to 6 weeks postvaccination.
Limitations |
This was an open-label study with no comparator.
Conclusions |
Most patients mounted immune responses to PPV; increases in antibody titers in these patients were consistent with those seen in healthy individuals.
Le texte complet de cet article est disponible en PDF.Key words : alefacept, biologics, pneumococcal polysaccharide vaccine, psoriasis, T cells, vaccines
Abbreviations used : AE, CI, IL, PPV, PSO, TNF
Plan
| The study and publication development were funded by Astellas Pharma Global Development Inc. |
|
| Disclosure: Dr Lynde has served as a consultant, researcher, and speaker for EMD Serono Inc, Astellas, Genentech, Amgen/Wyeth, Centocor, Ortho Biotech, Schering Canada, Leo Pharma, Abbott, Isotechnika, and Celgene. Dr Krell has served as a consultant, investigator, and speaker for and received funding for research from Biogen Idec and Astellas Pharma US; has served as consultant, investigator, and speaker for Genentech; was an investigator and speaker for Abbott Pharmaceuticals and Amgen; and was a speaker for Centocor. Dr Korman has served as a consultant, on advisory boards, and as a speaker for Abbott, Amgen, Astellas, Centocor, Genentech, and Novartis; was an investigator and received research funding from Abbott, Amgen, Astellas, Centocor, Genentech, and Novartis; and received fellowship funding from Centocor. Dr Mathes is a consultant for Astellas Pharma Global Development Inc, was formerly an employee of Biogen Idec, and is involved in clinical trials with alefacept. |
Vol 65 - N° 4
P. 799-806 - octobre 2011 Retour au numéro
Article précédent
- Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa
- Christoph Schlapbach, Tanja Hänni, Nikhil Yawalkar, Robert E. Hunger
- Outcome of 6 years of protocol use for preventing wrong site office surgery
- John Starling, Brett M. Coldiron
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?